Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Statins are widely used cholesterol-lowering agents that may have potential antitumor effect. Epidemiological studies on statin use and renal cell carcinoma (RCC) risk have been inconsistent.
The authors investigated the association between statin use and RCC risk in the Nurses' Health Study and Health Professionals Follow-Up Study. In total, 80,782 women and 37,869 men were followed for 14 years and 16 years, respectively. Regular statin use was assessed at baseline and was updated biennially during follow-up. RCC diagnosis was confirmed by medical record review.
Two hundred seventy-seven incident RCC cases (164 women and 113 men) were identified. Compared with no current use, the multivariate relative risks of current statin use were 0.68 (95% confidence interval, 0.46-1.00) in women and 1.17 (95% confidence interval, 0.75-1.82) in men. The results for ever versus never users of statins were similar. No dose-response relation with duration of statin use and RCC risk was observed. On subgroup analyses, statin use was associated with a reduced RCC risk among women who had no history of hypertension.
The current study indicated that statin use may be associated with a lower risk of RCC in women, although these results need to be investigated further.
Written by:
Liu W, Choueiri TK, Cho E. Are you the author?
Reference: Cancer. 2011 Jul 12. Epub ahead of print.
doi: 10.1002/cncr.26338
PubMed Abstract
PMID: 21751202
UroToday.com Renal Cancer Section
